Tarceva

AZ starts pursuit of lung cancer indication for Imfinzi

In that study, patients on Tagrisso had a PFS of 18.9 months, compared to just over 10 months for first-generation EGFR-targeting drugs, Roche's Tarceva (erlotinib) and

AZ buoyed by latest lung cancer data at ESMO

to just over 10 months for first-generation EGFR-targeting drugs, Roche's Tarceva (erlotinib) and AZ's own Iressa (gefitinib).

AZ gets rapid approval in China for Tagrisso

Moreover, nearly two thirds patients whose disease progresses after treatment with a first-line EGFR inhibitor - such as Iressa, Roche/Astellas' $2bn-a-year Tarceva (erlotinib) and Boehringer Ingelheim's Giotrif

Novocure’s chief commercial officer to step down

Previously, he was senior vice president for sales and marketing at OSI Pharmaceuticals, where he led the global commercialisation of Tarceva (erlotinib) from 2003 to 2011.

AZ's Tagrisso beats chemotherapy in lung cancer trial

The mutation develops in around two-thirds of patients who have received other EGFR inhibitors, such as Roche/Astellas' $2bn-a-year Tarceva (erlotinib), AstraZeneca's Iressa (gefitinib) and Boehringer

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]